Overview
Modified GRF (1–29) is a synthetic research peptide based on the N-terminal 29–amino acid segment of growth hormone–releasing factor (GRF). The sequence incorporates deliberate amino acid modifications intended to improve resistance to enzymatic degradation and enhance stability in experimental environments. This shortened analogue represents the functional GRF domain commonly examined in laboratory studies of endocrine signaling and peptide–receptor interactions.
In scientific literature, this compound is frequently identified as CJC-1295 without DAC, distinguishing it from long-acting variants that include drug affinity complex (DAC) modification. The non-DAC format is specifically employed in research designs focused on short-duration receptor activation, early signaling events, and time-dependent pathway responses under controlled preclinical conditions.
This material is supplied exclusively for laboratory research, including in-vitro experimentation and in-vivo animal model studies.
Biochemical Characteristics
Amino Acid Sequence:
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂
Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: 3,368.7 g/mol
Reported Synonyms: Modified GRF (1–29), CJC-1295 (No DAC)
The inclusion of D-alanine at position 2 is a common peptide-engineering strategy used to reduce enzymatic cleavage observed in native GRF sequences. C-terminal amidation is incorporated to promote structural consistency and support reproducible receptor interaction during in-vitro and in-vivo experimental analysis.
Research Applications
Modified GRF (1–29) is utilized in laboratory research as a tool compound for studying activation of the growth hormone–releasing hormone receptor (GHRHR) and associated intracellular signaling pathways. It is frequently applied in investigations examining ligand–receptor binding behavior, receptor activation kinetics, and second-messenger signaling under tightly controlled experimental conditions.
Common research applications include:
- GHRHR binding affinity and receptor kinetics assays
- Adenylate cyclase activation and cyclic AMP (cAMP) signaling measurements
- Structure–activity relationship (SAR) comparisons among GRF (1–29) analogues
- Endocrine and neuroendocrine signaling studies in cellular and animal research models
The absence of DAC modification allows researchers to evaluate transient signaling responses without prolonged receptor engagement or extended pharmacokinetic effects.
Pathway & Mechanistic Context
Modified GRF (1–29) interacts with the growth hormone–releasing hormone receptor, a class B G protein–coupled receptor primarily associated with Gs-protein signaling. In established experimental models, receptor engagement stimulates adenylate cyclase activity, leading to increased intracellular cAMP levels and activation of protein kinase A (PKA)–linked signaling cascades and downstream transcriptional regulators.
This signaling framework is widely used in preclinical research to explore receptor specificity, signal amplification, activation timing, and feedback regulation within endocrine and neuroendocrine systems.
Preclinical Research Summary
Preclinical investigations involving Modified GRF (1–29) have centered on receptor activation characteristics, comparative potency across GRF analogues, and intracellular signaling dynamics in cell-based models. In animal research systems, studies have examined endocrine-axis signaling modulation and peptide distribution patterns using established experimental endpoints.
Collectively, these studies contribute to foundational understanding of peptide hormone signaling and receptor pharmacology. All reported findings originate exclusively from non-clinical research environments.
Formulation & Analytical Verification
Modified GRF (1–29) is supplied as a lyophilized solid to support stability during storage and transport prior to laboratory use. Molecular identity and purity are verified using standard analytical methodologies, including high-performance liquid chromatography (HPLC) and mass spectrometry (MS).
Manufacturing and quality controls are performed under controlled laboratory conditions to promote batch consistency and support reproducibility across research applications.
Research Use Only (RUO) Notice
All products available on this website are provided solely for in-vitro laboratory research purposes. In-vitro studies are conducted outside of living organisms.
These materials are not drugs, medicines, or therapeutic agents and have not been approved by the U.S. Food and Drug Administration (FDA) for the diagnosis, treatment, prevention, or cure of any disease or medical condition.
